Solve Therapeutics

Executive Summary

Solve Therapeutics is a preclinical-stage genetic medicine company pioneering RNA-based therapeutics for rare diseases with well-defined genetic origins. Founded in 2021 and headquartered in Cambridge, MA, the company has raised $120 million to advance its pipeline of antisense oligonucleotide (ASO) and RNA interference (RNAi) candidates. Solve’s platform targets the root cause of disorders by precisely modulating gene expression, offering potential one-time or chronic treatments. With a focus on neurology and genetically homogeneous patient populations, the company aims to de-risk clinical development through rigorous biomarker-driven strategies. While still in preclinical stages, Solve’s substantial funding and clear scientific rationale position it to enter the clinic within the next 12-18 months. The company's ability to execute on lead candidate advancement and differentiate from competitors will be critical to its near-term value inflection.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Candidate70% success
• Q3 2026Preclinical Proof-of-Concept Data at Major Conference80% success
• Q1 2027New Financing or Partnership Announcement50% success